New strategies for targeting PD-1/PD-L1:degraders,bifunctional molecules and covalent inhibitors
10.11665/j.issn.1000-5048.2023112702
- VernacularTitle:靶向PD-1/PD-L1的新策略:降解剂、双功能分子及共价抑制剂
- Author:
Zhijie WANG
1
,
2
;
Xiaotong LIAO
;
Xia GUO
;
Jianjun CHEN
Author Information
1. 南方医科大学深圳医院, 深圳 518100
2. 南方医科大学药学院, 广州 510515
- Keywords:
PD-1/PD-L1;
tumor immunotherapy;
degraders;
bifunctional molecules;
covalent inhibitors
- From:
Journal of China Pharmaceutical University
2024;55(1):5-14
- CountryChina
- Language:Chinese
-
Abstract:
Programmed cell death protein-1(PD-1)/programmed cell death ligand-1(PD-L1)has been considered to be one of the most promising targets for tumor immunotherapy.At present,both monoclonal antibody drugs and small molecule inhibitors targeting PD-1/PD-L1 are facing bottlenecks.Numerous researchers have tried to explore different strategies to block the PD-L1/PD-L1 pathway,hoping to improve the effects of tumor immunotherapy.This review focuses on the degraders,bifunctional molecules and covalent inhibitors that target PD-L1,aiming to provide inspiring insights for the development of anti-PD-1/PD-L1 drugs.
